CD274 and neoplasm: PD-L1 expression has been shown to identify melanoma patients who are more likely to respond to PD-1 inhibitors.590 However, it is not recommended to take PD-L1 expression into account for treatment decisions because of the imperfect correlation between PD-L1 expression and clinical benefits from PD-1 inhibitors.525,591 Higher tumor mutational burden is associated with better response to ICBs, which is thought to enhance antitumor immune response through augmenting neoantigen formation.